JPWO2020017629A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020017629A5
JPWO2020017629A5 JP2020531380A JP2020531380A JPWO2020017629A5 JP WO2020017629 A5 JPWO2020017629 A5 JP WO2020017629A5 JP 2020531380 A JP2020531380 A JP 2020531380A JP 2020531380 A JP2020531380 A JP 2020531380A JP WO2020017629 A5 JPWO2020017629 A5 JP WO2020017629A5
Authority
JP
Japan
Prior art keywords
rgma
ham
inhibitor
htlv
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020531380A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020017629A1 (ja
JP7150286B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/028431 external-priority patent/WO2020017629A1/ja
Publication of JPWO2020017629A1 publication Critical patent/JPWO2020017629A1/ja
Publication of JPWO2020017629A5 publication Critical patent/JPWO2020017629A5/ja
Priority to JP2022148180A priority Critical patent/JP7475011B2/ja
Application granted granted Critical
Publication of JP7150286B2 publication Critical patent/JP7150286B2/ja
Priority to JP2024061895A priority patent/JP7703174B2/ja
Priority to JP2025100449A priority patent/JP2025134820A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020531380A 2018-07-19 2019-07-19 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法 Active JP7150286B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022148180A JP7475011B2 (ja) 2018-07-19 2022-09-16 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
JP2024061895A JP7703174B2 (ja) 2018-07-19 2024-04-08 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
JP2025100449A JP2025134820A (ja) 2018-07-19 2025-06-16 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018135925 2018-07-19
JP2018135925 2018-07-19
PCT/JP2019/028431 WO2020017629A1 (ja) 2018-07-19 2019-07-19 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022148180A Division JP7475011B2 (ja) 2018-07-19 2022-09-16 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法

Publications (3)

Publication Number Publication Date
JPWO2020017629A1 JPWO2020017629A1 (ja) 2021-08-02
JPWO2020017629A5 true JPWO2020017629A5 (cg-RX-API-DMAC7.html) 2022-07-01
JP7150286B2 JP7150286B2 (ja) 2022-10-11

Family

ID=69163691

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020531380A Active JP7150286B2 (ja) 2018-07-19 2019-07-19 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
JP2022148180A Active JP7475011B2 (ja) 2018-07-19 2022-09-16 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
JP2024061895A Active JP7703174B2 (ja) 2018-07-19 2024-04-08 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
JP2025100449A Pending JP2025134820A (ja) 2018-07-19 2025-06-16 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022148180A Active JP7475011B2 (ja) 2018-07-19 2022-09-16 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
JP2024061895A Active JP7703174B2 (ja) 2018-07-19 2024-04-08 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
JP2025100449A Pending JP2025134820A (ja) 2018-07-19 2025-06-16 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法

Country Status (16)

Country Link
US (1) US20210269535A1 (cg-RX-API-DMAC7.html)
EP (2) EP4656657A3 (cg-RX-API-DMAC7.html)
JP (4) JP7150286B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034055A (cg-RX-API-DMAC7.html)
CN (4) CN116850291A (cg-RX-API-DMAC7.html)
AU (1) AU2019306721B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000949A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112511A1 (cg-RX-API-DMAC7.html)
IL (1) IL280257A (cg-RX-API-DMAC7.html)
MX (1) MX2021000732A (cg-RX-API-DMAC7.html)
PE (2) PE20260298A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550134A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100561QA (cg-RX-API-DMAC7.html)
TW (2) TWI825131B (cg-RX-API-DMAC7.html)
WO (1) WO2020017629A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101113B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025070749A1 (cg-RX-API-DMAC7.html) * 2023-09-29 2025-04-03

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
WO2005087268A1 (ja) * 2004-03-11 2005-09-22 Bioclues, Inc 軸索再生促進剤
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102131571B (zh) 2008-09-02 2014-03-05 东丽电池隔膜株式会社 微孔性高分子膜、该膜的制备方法及该膜作为电池隔膜的应用
JP5552630B2 (ja) 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法
KR102284780B1 (ko) 2009-12-09 2021-08-02 미쓰비시 타나베 파마 코퍼레이션 T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법
CA2824515C (en) * 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
JP5963233B2 (ja) * 2011-12-07 2016-08-03 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法
JP6310845B2 (ja) * 2012-07-06 2018-04-11 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症患者の治療方法および治療剤
WO2016038084A1 (en) 2014-09-10 2016-03-17 AbbVie Deutschland GmbH & Co. KG Rgma fragment based diagnostic assay
CA2983898A1 (en) * 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TW202523689A (zh) * 2016-06-01 2025-06-16 美商艾伯維有限公司 治療脊髓損傷及疼痛之方法
US10772887B2 (en) * 2016-08-03 2020-09-15 Kagoshima University Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

Similar Documents

Publication Publication Date Title
CN111601791A (zh) Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
SA521422143B1 (ar) 15-pgdh مثبط
EA202193015A1 (ru) Ингибиторы cdk
JP1735298S (ja) 骨切り術用ウェッジ
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
CN113412260A (zh) 己酮糖激酶抑制剂及其用途
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途
JP2016523260A5 (cg-RX-API-DMAC7.html)
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
MA45984B1 (fr) Polytherapie pour la copd
JP1735297S (ja) 骨切り術用ウェッジ
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
JP2021513972A5 (cg-RX-API-DMAC7.html)
IL193252A0 (en) N-hydroxyacrylamide compounds
CN109661395A (zh) Pde4抑制剂
MX2019008181A (es) Inhibidores selectivos hdac6, metodos de preparacion y aplicacion de los mismos.
AR119159A1 (es) Tratamientos de angioedema
EA202190153A1 (ru) Составы ингибитора axl/mer
EA200801619A1 (ru) Способ улучшения фармакокинетики ингибиторов интегразы вич (варианты), набор и фармацевтическая композиция (варианты)
CN115666576A (zh) 一种治疗和/或预防冠状病毒引发的疾病的化合物及其应用
EA202190452A1 (ru) Ингибиторы cdk8/19
WO2020136298A3 (es) Inhibidores de la caspasa 1 para uso en el tratamiento de la anemia
CN115397411A (zh) 药物组合及其用途